Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quoin PharmaceuticalsSTU:2EB0 19 EBIT per Share is €-15.56 as of Mar. 2026. GuruFocus rates STU:2EB0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,173 Biotechnology companies, Quoin Pharmaceuticals ranks better than 96.59% on this metric.
Quoin Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was €-1.57.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-15.56.
During the past 3 years, the average EBIT per Share Growth Rate was 78.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 60.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Quoin Pharmaceuticals's EBIT per Share or its related term are showing as below:
STU:2EB0'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.5 Med: 47.8 Max: 78.5
Current: 78.5
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Quoin Pharmaceuticals was 78.50% per year. The lowest was -25.50% per year. And the median was 47.80% per year.
STU:2EB0's 3-Year EBIT Growth Rate is ranked better than 96.59% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs STU:2EB0: 78.50
Quoin Pharmaceuticals (STU:2EB0) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Quoin Pharmaceuticals EBIT per Share Related Terms
Quoin Pharmaceuticals EBIT per Share Historical Data
* Premium members only.
The historical data trend for Quoin Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quoin Pharmaceuticals (STU:2EB0) has a EBIT per Share of €-15.56 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Quoin Pharmaceuticals and its competitors. According to the industry distribution chart, Quoin Pharmaceuticals ranks #40 out of 1173 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Quoin Pharmaceuticals' EBIT per Share too high?
Quoin Pharmaceuticals' current EBIT per Share is €-15.56. Based on the distribution chart, Quoin Pharmaceuticals ranks #40 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Quoin Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Quoin Pharmaceuticals' EBIT per Share compare to RVPH and AIM?
According to the Biotechnology industry distribution chart, Quoin Pharmaceuticals ranks #40 out of 1173 companies for EBIT per Share. This places Quoin Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Quoin Pharmaceuticals and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quoin Pharmaceuticals's current EBIT per Share is €-15.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quoin Pharmaceuticals stock overvalued right now?
Quoin Pharmaceuticals (STU:2EB0) has a current EBIT per Share of €-15.56. The current EBIT per Share is €-15.56. Quoin Pharmaceuticals' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Quoin Pharmaceuticals (STU:2EB0), the current EBIT per Share is €-15.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
19GF Score
Get the complete analysis for STU:2EB0
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2EB0 has been successfully added to your 
